

LAHIVE
&
COCKFIELD
L L P



CONSULTORS AT LAW
128 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 727-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DI CORTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DAANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIORIOGIO
DEBRA J. MILASINIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. KAY, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHAN NANO
MICHAEL PHILLIPS *
LISA M. DIROCCO
HATHAWAY P. RUSSELL ***

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCORFIELD, JR.

PATENT AGENTS
THEODORE R. WEST
SHARNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS

MARIA LACOTRIPE ZACHARAKIS, Ph.D. **
CYNTHIA M. SOROOS
PETER W. IAN, Ph.D.
ELIHOO LEE
JENNIFER K. ROSENFELD
ALLAN TAMESHITI, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
PETER A. DIMATTIA
JOHNATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.
VINCENT P. LOCOSANO
MERIDETH C. ARNOLD

* Admitted in NY only
** Passed the Patent Bar Examination
*** Admitted in TX only

November 13, 2001

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application Serial No.: 09/852,400
Compositions, Kits, and Methods for Identification,
Assessment, Prevention, and Therapy of Psoriasis
Inventors: William L. Trepicchio et al.
Filed: May 9, 2001
Our Ref. No.: GFN-5405CP

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449; and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

November 13, 2001

Date

Amy E. Mandragouras, Esq. Reg. No. 36,207

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Amy E. Mandragouras, Esq.
Reg. No. 36,207
Attorney for Applicants

TECH CENTER 1600/2300

JAN 07 2002

RECEIVED

1623



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2930

JAN 07 2002

RECEIVED

Application of: William L. Trepicchio et al.

Group Art Unit: 1623

Serial No.: 09/852,400

Examiner:

Filed: May 9, 2001

For: Compositions, Kits, and Methods for
Identification, Assessment, Prevention, and Therapy
of Psoriasis

Attorney Docket No.: GFN-5405CP

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

11/13/01
Date of Signature and of Mail Deposit

By: 

Amy E. Mandragouras, Esq.
Reg. No. 36,207
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP




Amy E. Mandragouras, Esq.
Reg. No. 36,207
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: **November 13, 2001**

AEM/CLK/SXH/ipc
Enclosures

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-83	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO GFN-5405CP	SERIAL NO 09/852,400
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT William L. Trepicchio et al.	GROUP 1623
		FILING DATE May 9, 2001	



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

A1	Balendran N, et al. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. J Invest Dermatol. 1999 Sep;113(3):322-8
A2	Brown RM, et al. Transfection screening for primary defects in the pyruvate dehydrogenase E1alpha subunit gene. Hum Mol Genet. 1997 Aug;6(8):1361-7
A3	Capon F, et al. Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet. 1999 Dec;65(6):1798-800
A4	Coven TR, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997 Dec;133(12):1514-22
A5	Czubayko F, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997 Oct;3(10):1137-40
A6	Eisen MB, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
A7	Fredriksson T, et al. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44
A8	Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7
A9	Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442-7
A10	Gottlieb AB, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302-9

Examiner	Date Considered
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED

JAN 10 7 2002

ECHO CENTER 6004296

~~LIST OF PUBLICATIONS CITED BY APPLICANT~~

IP E (Use several sheets if necessary)

GFN-5405CP

69/852-400

APPLICANT

William L. Trepicchio et al

FILING DATE

May 9, 2001

GROUP

1623

01 P E (Use s
JAN 02 2002
FICE

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

Krueger JG, et al. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. *J Invest Dermatol.* 1990 Jun;94(6 Suppl):135S-140S

B2	Tamayo P, et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12
----	--

B3	Trepicchio WL, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. <i>J Clin Invest.</i> 1999 Dec;104(11):1527-37
----	--

B4	Trepicchio WL, et al. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. <i>J Immunol.</i> 1997 Dec 1;159(11):5661-70
----	--

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.